newsfilter
← Latest News
GlobeNewswire·

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go